Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2011

Open Access 01-12-2011 | Research

Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room

Authors: Alonso Montoya, Amparo Valladares, Luis Lizán, Luis San, Rodrigo Escobar, Silvia Paz

Published in: Health and Quality of Life Outcomes | Issue 1/2011

Login to get access

Abstract

Background

Despite the wide use of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a clinical setting to assess agitated patients, a validation study to evaluate its psychometric properties was missing.

Methods

Data from the observational NATURA study were used. This research describes trends in the use of treatments in patients with acute psychotic episodes and agitation seen in emergency departments. Exploratory principal component factor analysis was performed. Spearman's correlation and regression analyses (linear regression model) as well as equipercentile linking of Clinical Global Impression of Severity (CGI-S), Agitation and Calmness Evaluation Scale (ACES) and PANSS-EC items were conducted to examine the scale's diagnostic validity. Furthermore, reliability (Cronbach's alpha) and responsiveness were evaluated.

Results

Factor analysis resulted in one factor being retained according to eigenvalue ≥1. At admission, the PANSS-EC and CGI-S were found to be linearly related, with an average increase of 3.4 points (p < 0.001) on the PANSS-EC for each additional CGI-S point. The PANSS-EC and ACES were found to be linearly and inversely related, with an average decrease of 5.5 points (p < 0.001) on the PANSS-EC for each additional point. The equipercentile method shows the poor sensitivity of the ACES scale. Cronbach's alpha was 0.86 and effect size was 1.44.

Conclusions

The factorial analyses confirm the unifactorial structure of the PANSS-EC subscale. The PANSS-EC showed a strong linear correlation with rating scales such as CGI-S and ACES. PANSS-EC has also shown an excellent capacity to detect real changes in agitated patients.
Appendix
Available only for authorised users
Literature
1.
Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP: Expert Consensus Panel for Behavioral Emergencies, 2001. The Expert Consensus Guidelines Series. Treatment of behavioural emergencies. Postgraduate Medicine 2001, (Spec No):1–88. quiz 89–90
2.
Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP: Expert Consensus Panel for Behavioral Emergencies, 2005. The expert consensus guideline series. Treatment of behavioral emergencies. Journal of Psychiatric Practice 2005, 11: 5–108. 10.1097/00131746-200511001-00002PubMedCrossRef
3.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13: 261–276.PubMedCrossRef
4.
Emsley R, Rabinowitz J, Torreman M, RIS-INT-35 Early Psychosis Global Working Group: The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia Research 2003, 61: 47–57. 10.1016/S0920-9964(02)00302-XPubMedCrossRef
5.
Van den Oord EJ, Rujescu D, Robles JR, Gieling I, Birrell C, Bukszár J, et al.: Factor structure and external validity of the PANSS revisited. Schizophrenia Research 2006, 82: 213–223. 10.1016/j.schres.2005.09.002PubMedCrossRef
6.
Lindenmayer JP, Bossie CA, Kujawa M, Zhu Y, Canuso CM: Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology 2008, 4: 264–270. 10.1159/000128325CrossRef
7.
Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL: Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 2003, 23: 342–348. 10.1097/01.jcp.0000085406.08426.a8PubMedCrossRef
8.
Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM: The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). Journal of Child and Adolescent Psychopharmacology 2006, 16: 665–670. 10.1089/cap.2006.16.665PubMedCrossRef
9.
Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E: A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. Journal of Psychiatric Practice 2006, 12: 223–228. 10.1097/00131746-200607000-00004PubMedCrossRef
10.
Pascual JC, Madre M, Puigdemont D, Oller S, Corripio I, Diaz A, et al.: A naturalistic study: 100 consecutive episodes of acute agitation in a psychiatric emergency department. Actas Españolas de Psiquiatría 2006, 34: 239–244.PubMed
11.
Panjonk F, Holzbach R, Naber D: Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology (Berl.) 2002, 162: 29–36. 10.1007/s00213-002-1055-9CrossRef
12.
Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 2002, 59: 441–448. 10.1001/archpsyc.59.5.441PubMedCrossRef
13.
Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2002, 26: 494–504. 10.1016/S0893-133X(01)00365-7CrossRef
14.
Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2003, 28: 182–192. 10.1038/sj.npp.1300023CrossRef
15.
Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al.: A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 2003, 25: 1420–1428. 10.1016/S0149-2918(03)80129-7PubMedCrossRef
16.
San L, Arranz B, Querejeta I, Barrio S, De la Gandara J, Perez V: A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. European Psychiatry: the Journal of the Association of European Psychiatrists 2006, 21: 539–543.CrossRef
17.
Turczyński J, Bidzan L, Staszewska-Małys E: Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2004, 10: I74–180.
18.
Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA: Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Current Alzheimer Research 2007, 4: 81–93. 10.2174/156720507779939805PubMedCrossRef
19.
Nordstrom K, Allen MH: Managing the acutely agitated and psychotic patient. CNS Spectrums 2007, 12: 5–11.PubMed
20.
Montoya A, San L, Olivares JM, Pérez-Sola V, Casillas M, López-Carrero C, et al.: Clinical characteristics of agitated psychotic patients treated with an oral antipsychotics attended in the emergency room setting: NATURA study. International Journal of Psychiatry in Clinical Practice 2008, 12: 127–133. 10.1080/13651500701749859PubMedCrossRef
21.
Escobar R, San L, Pérez V, Olivares JM, Polavieja P, López-Carrero C, et al.: Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study. Actas Españolas de Psiquiatría 2008, 36: 151–157.PubMed
22.
Guy W: ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare publication, revised ed. National Institute of Mental Health, Rockville, MD; 1976.
23.
Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, et al.: The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. Journal of Evaluation in Clinical Practice 2008, 14: 979–983. 10.1111/j.1365-2753.2007.00921.xPubMedCrossRef
24.
Battaglia J, Lindborg SR, Alaka J, Meehan K, Wright P: Calming versus sedative effects of intramuscular olanzapine in agitated patients. The American Journal of Emergency Medicine 2003, 21: 192–198. 10.1016/S0735-6757(02)42249-8PubMedCrossRef
25.
Zumbo BD: Validity: foundational issues and statistical methodology. In Handbook of Statistics 26: Psychometrics. Edited by: Rao CR, Sinharay S. Elsevier, London; 2007.
26.
Zumbo BD, (Ed): Validity theory and the methods used in validation: perspectives from the social and behavioural sciences. In Special issue of the journal Social Indicators Resesarch: An International and Interdisciplinary Journal for Quality of Life Measurements. Volume 45. Amsterdam: Kluwer Acaddenic Press; 1998:1–359.
27.
Kolen MJ, Brennan RL: Test Equating, Scaling, and Linking: Methods and Practices. second edition. New York: Springer-Verlag; 2004.CrossRef
28.
Holland PW, Dorans NJ: Linking and equating. In Educational Measurement. 4th edition. Edited by: Brennan RL. Wesport, CT: Praeger Publishers; 2006.
29.
Dorans NJ, Pommerich M, Holland PW: Linking and aligning scores and scales. New York: Springer; 2007.CrossRef
30.
Guyatt GH, Walter SD, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Diseases 1987, 40: 171–178. 10.1016/0021-9681(87)90069-5CrossRef
31.
Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Medical Care 1989, 27: 178–189. 10.1097/00005650-198903001-00015CrossRef
32.
Brand A, Bradley MT, Best LA, Stoica G: Accuracy of effect size estimates from published psychological research. Perceptual and Motor Skills 2008, 106: 645–649. 10.2466/pms.106.2.645-649PubMedCrossRef
33.
Steinberg L, Thissen D: Using effect sizes for research reporting: examples using item response theory to analyze differential item functioning. Psychological Methods 2006, 11: 402–415. 10.1037/1082-989X.11.4.402PubMedCrossRef
34.
Cohen J: Statistical power analysis for the behavioural sciences. New York: Academic Press Inc; 1977.
35.
Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S: Extrapolation between measures of symptoms severity and change: an examination of the PANSS and CGI. Schizophrenia Research 2008, 98: 318–322. 10.1016/j.schres.2007.09.006PubMedCrossRef
36.
Laenen A, Alonso A, Molenberghs G, Vangeneugden T, Mallinckrodt CH: Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales. J Psychiatr Res 2009, 43: 730–8. 10.1016/j.jpsychires.2008.09.010PubMedCrossRef
37.
Alonso A, Laenen A, Molenberghs G, Geys H, Vangeneugden T: A unified approach to multi-item reliability. Biometrics 2010, 66: 1061–8. 10.1111/j.1541-0420.2009.01373.xPubMedCrossRef
38.
Wilhelm S, Schacht A, Wagner T: Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial. BMC Psychiatry 2008, 8: 61. 10.1186/1471-244X-8-61PubMedCentralPubMedCrossRef
39.
Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, et al.: Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophrenia Research 2008, 100: 342–348. 10.1016/j.schres.2007.12.480PubMedCrossRef
40.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR: What does the PANS mean? Schizophrenia Research 2005, 79: 231–238. 10.1016/j.schres.2005.04.008PubMedCrossRef
Metadata
Title
Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
Authors
Alonso Montoya
Amparo Valladares
Luis Lizán
Luis San
Rodrigo Escobar
Silvia Paz
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2011
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-9-18

Other articles of this Issue 1/2011

Health and Quality of Life Outcomes 1/2011 Go to the issue

Research

General anxiety, depression, and physical health in relation to symptoms of heart-focused anxiety-a cross sectional study among patients living with the risk of serious arrhythmias and sudden cardiac death

Research

Impact of stroke on health-related quality of life in diverse cultures: the Berlin-Ibadan multicenter international study

Research

Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND)

Research

Impact of childhood trauma on functionality and quality of life in HIV-infected women

Research

Analysis of the construct of dignity and content validity of the patient dignity inventory

Research

Longitudinal association of physical activity and sedentary behavior during leisure time with health-related quality of life in community-dwelling older adults